ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Hydroxychloroquine"

  • Abstract Number: 2539 • 2019 ACR/ARP Annual Meeting

    Patient Perception of Benefit and Risks Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus (SLE)

    Sooyeon Kwon1, Jessica Farrell 2, Sarfaraz Hasni 3 and Shubhasree Banerjee 2, 1The Center For Rheumatology, Loudonville, NY, 2The Center for Rheumatology, LLC, Albany, NY, 3NIAMS, National Institutes of Health, Bethesda, MD

    Background/Purpose: Hydroxychloroquine (HCQ) is recommended in all patients with systemic lupus erythematosus (SLE).  Studies suggest that a significant proportion of subjects are non-adherent to daily…
  • Abstract Number: 2541 • 2019 ACR/ARP Annual Meeting

    Pharmacokinetics of Hydroxychloroquine in Systemic Lupus Erythematosus Patients with Renal Impairment

    Naoto Yokogawa1, Masayuki Hashiguchi 2, Yoshiki Nagai 3, Kota Shimada 4, Shoji Sugii 1, Miho Oshima 5, Keigo Setoguchi 6 and Mikiko Shimizu 7, 1Department of Rheumatic Diseases, Tokyo Metropoitan Tama Medica Center, Fuchu, Japan, 2Division for Evaluation and Analysis of Drug Information, Faculty of Pharmacy, Keio University, Tokyo, Japan, 3Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Fuchu, Japan, 4Department of Rheumatic Diseases, Tokyo Metropoitan Tama Medica Center, Fuchu, 5Division of Rheumatology, Mitsui Memorial Hospital, Tokyo, Japan, 6Tokyo Metropolitan Cancer and Infectious Dease Center Komagome Hospital, Tokyo, Tokyo, Japan, 7Department of Drug Metabolism and Pharmacokinetics, Faculty of Pharmaceutical Sciences, Aomori University, Aomori, Japan

    Background/Purpose: A low glomerular filtration rate (GFR: < 60 mL/min/1.73 m2) is an established risk of hydroxychloroquine (HCQ) retinopathy and is presumably related to higher…
  • Abstract Number: 2560 • 2019 ACR/ARP Annual Meeting

    Factors Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus Patients with End Stage Renal Disease

    Maria Salgado Guerrero1, Alejandra Londono Jimenez 2, Chrisanna Dobrowolsky 2, Shudan Wang 2, Wenzhu B. Mowrey 3 and Anna Broder 2, 1Internal Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, 2Rheumatology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, 3Albert Einstein College of Medicine, Bronx, NY

    Background/Purpose: Hydroxychloroquine (HCQ) use in SLE has been associated with a lower risk of end-organ damage, SLE flares, and thrombosis1,2. However the benefits of HCQ…
  • Abstract Number: 2567 • 2019 ACR/ARP Annual Meeting

    Prospective Evaluation of American Academy of Ophthalmology Low Dose Hydroxychloroquine Recommendation in Stable Lupus Nephritis with High-Risk Retinopathy: Lipid Profile and Flare Rates

    Tatiana Pedrosa 1, Sandra G. Pasoto 1, Emily Yuki2, Nadia Aikawa 1, Eduardo Borba 1, Julio Ferreira Filho 1, Pedro Carricondo 3, Caio Zanetti 1, Paola Conde 1, Nicole Fontoura 1, Paschoalina Romano 4, Valdemir Carvalho 5, Clovis Silva 6 and Eloisa Bonfa 7, 1Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, 2Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., São Paulo, Brazil, 3Ophtalmology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, 4Division of Central Laboratory, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, 5Fleury Group, Sao Paulo, Brazil, Sao Paulo, Brazil, 6Pediatric Rheumatology Unit, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, 7Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil

    Background/Purpose: Hydroxychloroquine (HCQ) is the most well established therapy for SLE, as it provides several beneficial properties, such as favorable effects on lipid profile, reduced…
  • Abstract Number: 320 • 2019 ACR/ARP Annual Meeting

    Hydroxychloroquine (HCQ) Prescribing Habits and Provider Opinion on Dosing Guidelines in the Rheumatology and Dermatology Practices of an Academic Institution

    Rebecca Overbury1, Jakrapun Pupaibool 2, Christopher Hansen 3, Daniel Clegg 4 and Dorota Lebiedz-Odrobina 5, 1Assisstant Professor, University of Utah, Salt Lake City, UT, 2University of Utah, Division of Infectious Diseases, Salt Lake City, UT, 3University of Utah, Department of Dermatology, Salt Lake City, UT, 4University of Utah, Salt Lake City, UT, 5University of Utah, Division of Rheumatology, Salt Lake City, UT

    Background/Purpose: Research has shown potential retinal toxicity rates from HCQ as high as 7.5%. Research suggests toxicity is dose-related. In 2016, the American Academy of…
  • Abstract Number: 2569 • 2019 ACR/ARP Annual Meeting

    Guidelines on Prescribing and Monitoring Antimalarials in Rheumatic Diseases: A Systematic Review

    Gemma Cramarossa1, Janet Pope 2 and Matthew Turk 3, 1Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada, 2Western University, London, ON, Canada, 3University of Western Ontario, London, ON, Canada

    Background/Purpose: The purpose of this systematic review was to identify existing guidelines for antimalarial prescribing and monitoring in rheumatic diseases, specifically for hydroxychloroquine, and how…
  • Abstract Number: 321 • 2019 ACR/ARP Annual Meeting

    Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Rheumatoid Arthritis and Systemic Lupus Erythematosus

    Tara Skorupa1 and Robert Shmerling 1, 1Beth Israel Deaconess Medical Center / Harvard Medical School, Boston, MA

    Background/Purpose: Hydroxychloroquine (HCQ) is a commonly prescribed medication for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and other rheumatic diseases. However, HCQ may cause retinal…
  • Abstract Number: 2573 • 2019 ACR/ARP Annual Meeting

    Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus: Comparison of Whole Blood and Serum Levels

    Benoit Blanchet 1, Jallouli Moez 2, Marie Allard 3, veronique le guern 4, Jean-Charles Piette 5, Noémie Jourde-Chiche 6 and Nathalie Costedoat-Chalumeau7, 1Cochin, Paris, France, 2sfax, SFAX, Tunisia, 3Hôpital Bichat Claude-Bernard, Paris, France, 4APHP, paris, France, 5Hôpital Pitié-Salpêtrière, Paris, France, 6APHM, Marseille, Marseille, France, 7Cochin University Hospital, Paris, France

    Background/Purpose: Hydroxychloroquine (HCQ) levels can be measured in whole blood as well as in serum but both methods have never been compared. Cut offs for…
  • Abstract Number: 322 • 2019 ACR/ARP Annual Meeting

    Hydroxychloroquine Retinal Screening and Dosing in an Unique Rheumatologic Patient Population

    Leanna Wise1, Stavros Savvas 2 and Elizabeth Ortiz 2, 1LAC+USC/Keck Medicine of USC, Los Angeles, CA, 2LAC+USC/Keck Medicine of USC, Los Angeles

    Background/Purpose: Hydroxychloroquine (HCQ) is used in many rheumatologic diseases. The American Academy of Ophthalmology (AAO) put forth guidelines in 2012 regarding retinal screening and dosing…
  • Abstract Number: 2579 • 2019 ACR/ARP Annual Meeting

    A Quality Improvement Project in Determining If Cardiac Enzymes Play a Role in Surveillance of Possible Hydroxychloroquine Induced Cardiotoxicity

    Eric Liu1 and Andras Perl 2, 1SUNY Upstate University Medical Center, Syracuse, NY, 2SUNY Upstate Medical University, Syracuse, NY

    Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used medication in our field of work with retinal toxicity being a known possible long-term side effect of the…
  • Abstract Number: 896 • 2019 ACR/ARP Annual Meeting

    Hydroxychloroquine Use and Cardiovascular Events Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis

    April Jorge1, Na Lu 2, Hyon K. Choi 1, John Esdaile 3, Diane Lacaille 4 and J. Antonio Avina-Zubieta 5, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hosptial, Boston, MA, 3Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada, 4Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada, 5Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Hydroxychloroquine (HCQ) is near-universally recommended for patients with SLE and is often used in the treatment of RA. Use of HCQ has been associated…
  • Abstract Number: 2581 • 2019 ACR/ARP Annual Meeting

    Clinical Impact of Decreasing Hydroxychloroquine Dose According to the 2016 American Academy of Ophthalmology Guidelines in Patients with Systemic Lupus Erythematosus

    Nicolle Medina-Cintrón1, Ileana Vázquez-Otero 1, Mariangelí Arroyo-Ávila 1, Lorena González-Sepúlveda 1 and Luis Vilá 1, 1University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico

    Background/Purpose: Hydroxychloroquine (HCQ) is one of the main drugs used for the treatment of systemic lupus erythematosus (SLE). Nonetheless, HCQ-induced retinal toxicity remains a major…
  • Abstract Number: 1130 • 2019 ACR/ARP Annual Meeting

    The Risk of Toxic Retinopathy Among Patients on Hydroxychloroquine

    Abdulrahman Alrashid1, Millicent Anne Stone 2, Nigel Davies 2 and David D'Cruz 3, 1King Abdulaziz Medical City - Riyadh, Riyadh, Saudi Arabia, 2Guy's and St Thomas Foundation Trust, London, United Kingdom, 3The Louise Coote Lupus Unit, Guy's Hospital, London, England, United Kingdom

    Background/Purpose: Background: Hydroxychloroquine (HCQ) is widely used in treatment of autoimmune rhuematological diseases. In particular, systemic lupus erythermatosus where it proved to prevent disease flare, reduce…
  • Abstract Number: 2829 • 2019 ACR/ARP Annual Meeting

    Improving SLE Care by Enhancing Medication Adherence Using a Tailored Clinic Intervention: HCQ-Crosswalk

    Shivani Garg1, Betty Chewning 2, Karen Hansen 3, Beth Martin 2 and Christie Bartels 1, 1University of Wisconsin School of Medicine and Public Health, Madison, WI, 2UW - School of Pharmacy, Madison, Madison, 3UW Madison, Madison

    Background/Purpose: Up to 83% of patients with SLE are nonadherent to hydroxychloroquine (HCQ) which results in a 36% higher risk of renal failure, and 8-fold…
  • Abstract Number: 1748 • 2019 ACR/ARP Annual Meeting

    Incidence of Retinopathy in Individuals Who Initiated Hydroxychloroquine Therapy During Childhood

    Sara Patrizi1, Douglas Stram 2, Miranda Weintraub 3 and Alexandra Aminoff 1, 1Kaiser Permanente, Department of Pediatrics, Oakland, 2Kaiser Permanente Northern California, Division of Research, Oakland, 3Kaiser Permanente, Department of Graduate Medical Education, Oakland

    Background/Purpose: Hydroxychloroquine (HCQ), a medication used to treat Systemic Lupus Erythematosus (SLE), Discoid Lupus Erythematosus (DLE) and Sjogren’s Syndrome (SS), reduces disease flare-ups, organ damage,…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology